Latest News and Press Releases

Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated WVE-004 did not show clinical...

Preclinical data published in Molecular Therapy Nucleic Acids demonstrate that WVE-004 potently reduces C9orf72 transcriptional variants and poly(GP) dipeptide repeat proteins in mice for at least six...

Reductions in poly(GP), a key disease biomarker indicating target engagement, observed across all treatment groups after single doses Extending dose observation period from three months (day 85) to...

First clinical dosing of a compound using PN backbone chemistry modifications Enrolling participants with C9-ALS, C9-FTD or mixed phenotype FOCUS-C9 is adaptive to enable rapid optimization of...

Data from 32 mg cohorts of both PRECISION-HD trials and PRECISION-HD OLE trials expected in 1Q 2021 C9orf72 and SNP3 clinical trial applications on track to be submitted in 4Q 2020 ADAR editing...

CAMBRIDGE, Mass., May 18, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...

CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious,...